0370 270 6000

Browne Jacobson advises shareholders on sale of lab equipment distributor business Medline Scientific to global life science provider

19 January 2022

Browne Jacobson’s award-winning corporate dealmakers have advised the shareholders of Medline Scientific on its sale to diversified global provider of life science reagents, tools, instruments and other consumables, Calibre Scientific for undisclosed consideration.

Browne Jacobson senior associate, Joel Nixon who is based in the firm’s Birmingham office led on the transaction with the support of Manchester based associate Bethany Pickup.

Established over 30 years ago, Medline Scientific is one of the UK’s leading independent distributors of laboratory products and equipment. Its diverse client base is made up of UK and international institutions and organisations that cut across various markets including clinical, life science, industrial and research.

Calibre Scientific which is based in Los Angeles, California has a global client portfolio that extends across 175 countries.

Mark Duffy, Founder of Medline Scientific said: “I am delighted to partner with Calibre Scientific - their vision aligns perfectly with ours, as does their overall growth strategy in the UK distribution market and beyond. Calibre Scientific is a great platform with the resources to take Medline to the next level, and I’m very excited to see what the future brings for Medline, as part of Calibre Scientific.

“I also want to thank the Browne Jacobson team for their support on this key business move. Their expertise in the sector and in the corporate finance space is spot on and they gave us strategically focused high-quality advice throughout, ensuring the transaction went smoothly for all parties involved.”

Joel Nixon added: “We are delighted to have advised Mark and the other shareholders on this sale which enables them to work with Calibre Scientific to accelerate the further growth of the business and open up new income streams on a global level. The transaction demonstrates our corporate finance credentials in the health tech, medical device and consumable space at an international level. 

Browne Jacobson’s national corporate finance practice is ranked by Experian as one of the country’s leading corporate finance teams, with over 30 corporate and banking & finance expert lawyers delivering complex layered corporate and banking transactions. The team advises domestic and international companies from fast growing start-ups to blue chip corporations on all stages of the business life cycle from capital and finance raising, through to mergers and acquisitions, and ultimately to succession or exit planning with particular expertise in the private equity market.

Focus on...

Press releases

Browne Jacobson appoints its first Non-Executive to Chair to support its corporate sector strategy board

Law firm Browne Jacobson has appointed leading General Counsel (GC), Anneliese Reinhold as the first Non-Executive Chair of its corporate sectoral strategy board, the first of several sector-driven appointments.


Legal updates

Integrated Care Boards and preventing NHS fraud

On 7 July this year, NHS England published its statutory guidance for Integrated Care Boards (ICBs) and with it set out the ICBs’ role and responsibilities and how they should collaborate, interact and carry out their anti-fraud, bribery and corruption functions in concert with NHS England.



IR35 rules to be scrapped from April 2023

The Chancellor’s recent mini-budget provided a significant announcement for business as it was confirmed that the off-payroll working rules (known as “IR35”) put in place for public and private sector businesses from 2017 and 2021 will be scrapped from April 2023.


Legal updates

CCGs’ conduct “sufficiently serious” for award of damages in High Court procurement case

This case provides a reminder to contracting authorities that whilst the bar for an award of damages in procurement cases is high, following the Supreme Court ruling in Energy Solutions EU Ltd v Nuclear Decommissioning Authority [2017] 1 WLR 1373, it is not insurmountable when a contracting authority has acted with disregard to the Public Contracts Regulations 2015 (PCRs). There is also further guidance as to the use of frameworks